Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Roche's Giredestrant?
Giredestrant is a small molecule commercialized by Roche, with a leading Phase III program in Breast Cancer;Metastatic Breast Cancer;Human Epidermal...
Giredestrant by Genentech USA for Solid Tumor: Likelihood of Approval
Giredestrant is under clinical development by Genentech USA and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
Giredestrant by Genentech USA for Breast Cancer: Likelihood of Approval
Giredestrant is under clinical development by Genentech USA and currently in Phase III for Breast Cancer. According to GlobalData, Phase...